Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap.
10/4/23 Free

Executive/Senior Manager

400,000 0.6684%
1/2/23 Free

Chief Technology Officer

400,000 0.6686%
1/2/23 Free

Chief Operating Officer

400,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 2.95M
+0.93%+6.97%+59.60%+69.78% 57.28B
-1.92%+6.03%+40.64%+80.66% 54.99B
-0.46%-1.29%+2.86%+425.15% 23.18B
-2.97%-2.35%-22.53%-15.34% 22.59B
-0.66%+1.52%+21.38%-7.30% 20.46B
-1.34%+0.51%+26.03%-28.68% 17.56B
0.00%+1.98%+34.55%+546.54% 15.67B
-1.30%-5.02%+170.77%+310.94% 14.46B
-0.50%-0.98%+21.43%+179.36% 13.92B
Average -2.16%+1.28%+39.41%+173.46% 26.68B
Weighted average by Cap. -0.80%+2.10%+39.19%+136.78%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock